We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Gastroenterology

Gastroenterology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
Clinical UpdatesALG-000184Capsid Assembly Modulator

Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial

By MedXY|Mar 2, 2026

This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease
GastroenterologyCrohn’s disease肠内营养

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease

By MedXY|Mar 2, 2026

The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-te

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Gastroenterologyneoadjuvant therapyPancreatic Cancer

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

By MedXY|Mar 2, 2026

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision
Gastroenterologybiomarkersliver transplantation

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

By MedXY|Feb 21, 2026

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially tr

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority
Gastroenterologyclinical trialLaparoscopy

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority

By MedXY|Feb 19, 2026

The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
GastroenterologyHepatologyliver fibrosis

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
Gastroenterologyefimosfermin alfaliver fibrosis

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

By MedXY|Feb 16, 2026

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

The Age Gap Penalty: Why Donor-Recipient Mismatch Shortens Graft Life in Adolescent Liver Transplants
Gastroenterologygraft survivalliver transplant

The Age Gap Penalty: Why Donor-Recipient Mismatch Shortens Graft Life in Adolescent Liver Transplants

By MedXY|Feb 10, 2026

A nationwide study reveals that adolescent liver transplant recipients receiving grafts from donors 10+ years older face a 12.7% reduction in 10-year graft survival. Expanding allocation radii could improve access to age-matched organs and

Time-Varying Risks in Colorectal Adenoma Recurrence: Why Histology and Demographics Demand a Personalized Surveillance Calendar
GastroenterologyColorectal Adenomaprecision oncology

Time-Varying Risks in Colorectal Adenoma Recurrence: Why Histology and Demographics Demand a Personalized Surveillance Calendar

By MedXY|Feb 5, 2026

A massive cohort study reveals that colorectal adenoma recurrence risk is not static; high-grade dysplasia, villous histology, obesity, and sex-based factors exhibit distinct time-varying patterns, necessitating a shift toward personalized,

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window
Diabetes & Endocrinologynew-onset diabetesoncology

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

By MedXY|Feb 4, 2026

A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
Gastroenterologyclinical trialsgastroenterology

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

By MedXY|Feb 4, 2026

A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints
Gastroenterologyclinical trialGastroparesis

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

By MedXY|Feb 3, 2026

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment
Gastroenterologyclinical trialsgastroenterology

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment

By MedXY|Feb 3, 2026

This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti

Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial
Gastroenterologygastroenterology急性膵炎

Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial

By MedXY|Feb 2, 2026

The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this hig

Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
Gastroenterologyacute pancreatitisERCP

Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice

By MedXY|Jan 27, 2026

The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasiz

Incident Splenomegaly: Defining Clinical Thresholds for Hematologic Cancer and Liver Disease Risk
GastroenterologyHematology-oncologyliver disease

Incident Splenomegaly: Defining Clinical Thresholds for Hematologic Cancer and Liver Disease Risk

By MedXY|Jan 29, 2026

This large-scale prospective cohort study identifies specific spleen length and volume thresholds that significantly increase the 5-year risk of hematologic malignancies and liver disease, providing a data-driven framework for clinical work

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
Diabetes & EndocrinologyBerberineChuyển hóa mỡ máu

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

By MedXY|Jan 24, 2026

The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont

Mediterranean Diet Outperforms Traditional Dietary Advice for Irritable Bowel Syndrome: A Landmark Randomized Trial
GastroenterologyClinical Nutritiongastroenterology

Mediterranean Diet Outperforms Traditional Dietary Advice for Irritable Bowel Syndrome: A Landmark Randomized Trial

By MedXY|Jan 20, 2026

A randomized clinical trial published in the Annals of Internal Medicine reveals that the Mediterranean diet is superior to traditional dietary advice for managing IBS symptoms, offering a nutrient-dense, sustainable first-line intervention

Interactive Mobile Coaching Improves Long-Term Quality of Life and Symptom Management After Gastrectomy
GastroenterologyGastric CancermHealth

Interactive Mobile Coaching Improves Long-Term Quality of Life and Symptom Management After Gastrectomy

By MedXY|Jan 20, 2026

A randomized controlled trial demonstrates that early interactive human coaching via a mobile app improves long-term quality of life, reduces dyspnea, and eases eating restrictions in postgastrectomy patients, particularly among younger and

Preoperative Nutritional Support Significantly Reduces Postoperative Enterocolitis in Children with Hirschsprung Disease: A Multicenter Randomized Controlled Trial
GastroenterologyNutritional Support

Preoperative Nutritional Support Significantly Reduces Postoperative Enterocolitis in Children with Hirschsprung Disease: A Multicenter Randomized Controlled Trial

By MedXY|Jan 20, 2026

A multicenter RCT demonstrates that preoperative nutritional support reduces the incidence of Hirschsprung-associated enterocolitis (HAEC) from 29.09% to 7.27%, offering a critical strategy for improving surgical outcomes in pediatric patie

Prev
15 / 25
1…1314151617…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles